Pfizer, a pharmaceutical giant, has faced challenges with sales slipping post-pandemic and a looming patent cliff. Despite this, the company is developing 108 drug candidates and remains a generous dividend payer with a yield of almost 7%. On the other hand, Realty Income, a top REIT, offers a high-yield dividend of 5.4% and pays out dividends monthly. With a strong business model and a portfolio of 15,600 properties, Realty Income continues to thrive with a 98.6% occupancy rate and growing revenue. Both Pfizer and Realty Income present compelling investment opportunities for dividend-seeking investors.

Read more at Nasdaq: 2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever